Inspecting these targets further: since 2005, DKK1 has been shown to modulate bone fragility in RA patients19, PML has been shown to inhibit Fas-mediated apoptosis of FLSs from RA patients20, and SIRT1 over-expression promotes pro-inflammatory cytokine production in FLSs21. Here, FAS is linked to rheumatoid arthritis.